bioMérieux - 2017 Financial Results

28 February, 2018

February 28, 2016 – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on February 27 under the chairmanship of Alexandre Mérieux and approved the audited consolidated financial statements for the year ended December 31, 2017.

Excellent sales momentum in 2017 with a 10.2% increase in sales, at constant exchange rates and scope of consolidation:

  • €2,288 million in sales
  • Up 8.8% as reported

Strong 12.4% increase in contributive operating income before non-recurring items to €335 million, in line with the objectives set

Fast growth in free cash flow to €164 million versus €85 million in 2016

2018 objectives:

  • Organic growth in sales of between 8% and 9%, at constant exchange rates and scope of consolidation
  • Contributive operating income before non-recurring items of between €325 million and €345 million, despite a negative currency impact anticipated at around €40 million

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux delivered another solid operating and financial performance in 2017. Thanks to a robust sales momentum and careful control of operating expenses, the Company recorded sharp increases in contributive operating income before nonrecurring items, net income and free cash flow. Buoyed by these results, we head into 2018 with the ambition to sustain this dynamic while strengthening our commitment to innovation and R&D.”

Download the Full Press Release:

Download
Pioneering Diagnostics